Bortezomib- and Thalidomide-Induced Peripheral Neuropathy (PN) in Multiple Myeloma (MM): Clinical and Molecular Analysis of 474 Patients Treated with Thalidomide-Dexamethasone (TD) or Bortezomib-TD (VTD)

被引：0

作者：

Tacchetti, Paola ^{[1
]}

Terragna, Carolina ^{[1
]}

Catania, Gioacchino ^{[2
]}

Marcatti, Magda ^{[3
]}

Nozza, Andrea ^{[3
]}

Ferrara, Felicetto ^{[4
]}

Nobile, Francesco ^{[5
]}

Califano, Catello ^{[6
]}

Baraldi, Anna ^{[7
]}

Gallamini, Andrea ^{[8
]}

Musto, Pellegrino ^{[9
]}

Tosi, Patrizia ^{[10
]}

Galieni, Piero ^{[11
]}

Pezzi, Annalisa ^{[1
]}

Lanza, Francesco ^{[12
]}

Ceccolini, Michela ^{[13
]}

Ballerini, Filippo ^{[2
]}

Catalano, Lucio

Cangialosi, Clotilde ^{[14
]}

Lazzaro, Antonio ^{[15
]}

Paladini, Giorgio ^{[16
]}

Mozzana, Ruggero ^{[17
]}

Zannetti, Beatrice Anna ^{[1
]}

Pinotti, Graziella ^{[17
]}

Elice, Francesca ^{[18
]}

Baccarani, Michele ^{[1
]}

Boccadoro, Mario ^{[19
]}

Cavaletti, Guido ^{[20
]}

Cavo, Michele ^{[1
]}

机构：

[1] Univ Bologna, Sch Med, Seragnoli Inst Hematol, Bologna, Italy

[2] GIMEMA Italian Myeloma Network, Genoa, Italy

[3] GIMEMA Italian Myeloma Network, Milan, Italy

[4] GIMEMA Italian Myeloma Network, Naples, Italy

[5] GIMEMA Italian Myeloma Network, Reggio Di Calabria, Italy

[6] GIMEMA Italian Myeloma Network, Salerno, Italy

[7] GIMEMA Italian Myeloma Network, Alessandria, Italy

[8] GIMEMA Italian Myeloma Network, Cuneo, Italy

[9] GIMEMA Italian Myeloma Network, Potenza, Italy

[10] GIMEMA Italian Myeloma Network, Rimini, Italy

[11] GIMEMA Italian Myeloma Network, Ascoli Piceno, Italy

[12] GIMEMA Italian Myeloma Network, Cremona, Italy

[13] GIMEMA Italian Myeloma Network, Forli, Italy

[14] GIMEMA Italian Myeloma Network, Palermo, Italy

[15] GIMEMA Italian Myeloma Network, Piacenza, Italy

[16] GIMEMA Italian Myeloma Network, Trieste, Italy

[17] GIMEMA Italian Myeloma Network, Varese, Italy

[18] GIMEMA Italian Myeloma Network, Vicenza, Italy

[19] GIMEMA Italian Myeloma Network, Turin, Italy

[20] Univ Milano Bicocca, Dept Neurosci & Biomed Technol DNTB, Monza, Italy

来源：

BLOOD | 2011年 / 118卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：794 / 795

页数：2

共 40 条

[1] Bortezomib(Velcade®)-Thalidomide-Dexamethasone (VTD) Is Superior to Thalidomide-Dexamethasone (TD) In Patients with Multiple Myeloma (MM) Progressing or Relapsing After Autologous Transplantation.
Garderet, Laurent
Iacobelli, Simona
Moreau, Philippe
Dib, Mamoun
Caillot, Denis
Niederwieser, Dietger W.
Masszi, Tamas
Fontan, Jean
Michallet, Mauricette
Gratwohl, Alois
Milone, Giuseppe
Doyen, Chantal
Pegourie, Brigitte
Hajek, Roman
Casassus, Philippe
Kolb, Brigitte
Chaleteix, Carine
Hertenstein, Bernd
Onida, Francesco
Ludwig, Heinz
Vekemans, Marie Christiane
Ketterer, Nicolas
Daguenel, Anne
Gorin, Norbert C.
Harousseau, Jean Luc
de Witte, Theo
Morris, Curly
Gahrton, Gosta
[J]. BLOOD, 2010, 116 (21) : 1254 - 1254
[2] A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD
Cavo, Michele
Tacchetti, Paola
Patriarca, Francesca
Petrucci, Maria Teresa
Pantani, Lucia
Galli, Monica
Di Raimondo, Francesco
Crippa, Claudia
Bringhen, Sara
Offidani, Massimo
Narni, Franco
Montefusco, Vittorio
Zamagni, Elena
Spadano, Tonino
Pescosta, Norbert
Baldini, Luca
Cellini, Claudia
Caravita, Tommaso
Ledda, Antonio
Falcone, Antonietta
Tosi, Patrizia
Nozzoli, Chiara
Zambello, Renato
Masini, Luciano
Agostini, Paola
Fiacchini, Mauro
Baccarani, Michele
[J]. BLOOD, 2009, 114 (22) : 148 - 149
[3] CLINICAL AND MOLECULAR ANALYSIS OF BORTEZOMIB- AND THALIDOMIDE-INDUCED PERIPHERAL NEUROPATHY (PN) IN MULTIPLE MYELOMA (MM): ANALYSIS FROM THE GIMEMA-MMY-3006 TRIAL
Tacchetti, P.
Terragna, C.
Patriarca, F.
Petrucci, M. T.
Zamagni, E.
Rossi, G.
Offidani, M.
Narni, F.
Cellini, C.
Pantani, L.
Baldini, L.
di Toritto, T. Caravita
Nozzoli, C.
Masini, L.
Martello, M.
Derudas, D.
De Stefano, V.
Catania, G.
Pezzi, A.
Ferrara, F.
Nobile, F.
Baccarani, M.
Cavaletti, G.
Cavo, M.
[J]. HAEMATOLOGICA, 2012, 97 : 118 - 118
[4] Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study
Tacchetti, Paola
Terragna, Carolina
Galli, Monica
Zamagni, Elena
Petrucci, Maria Teresa
Pezzi, Annalisa
Montefusco, Vittorio
Martello, Marina
Tosi, Patrizia
Baldini, Luca
Peccatori, Jacopo
Ruggieri, Miriana
Pantani, Lucia
Lazzaro, Antonio
Elice, Francesca
Rocchi, Serena
Gozzetti, Alessandro
Cavaletti, Guido
Palumbo, Antonio
Cavo, Michele
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (12) : 1085 - 1091
[5] Bortezomib (velcade(R))-thalidomide-dexamethasone (VTD) vs thalidomide-dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM)
Cavo, Michele
Patriarca, Francesca
Tacchetti, Paola
Galli, Monica
Perrone, Giulia
Petrucci, Maria Teresa
Brioli, Annamaria
Bringhen, Sara
Pantani, Lucia
Tosi, Patrizia
Crippa, Claudia
Zamagni, Elena
Di Raimondo, Francesco
Narni, Franco
Cellini, Claudia
Ceecolini, Michela
Pescosta, Norbert
Goldaniga, Maria Cecilia
Montefusco, Vittorio
Callea, Vincenzo
De Stefano, Valerio
Caravita, Tommaso
Boccadoro, Mario
Baccarani, Michele
[J]. BLOOD, 2007, 110 (11) : 30A - 30A
[6] Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) as induction treatment for newly diagnosed Multiple Myeloma (MM) is associated with a lower rate of Second Primary Malignancies (SPMs) compared to Thalidomide-Dexamethasone (TD)
Brioli, A.
Pezzi, A.
Muegge, L-O
Derudas, D.
Petti, M. C.
Zannetti, B. A.
Ferrara, F.
Rocchi, S.
Nobile, F.
Baraldi, A.
Musto, P.
Lanza, F.
Mancuso, K.
Canepa, L.
Catalano, L.
Lazzaro, A.
Pinotti, G.
Boccadoro, M.
Hochhaus, A.
Cavo, M.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 69 - 69
[7] Treatment of Multiple Myeloma: Thalidomide-, Bortezomib-, and Lenalidomide-Induced Peripheral Neuropathy
Koeppen, Susanne
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 (09) : 506 - 513
[8] Retrospective comparison of transplant outcomes in patients with multiple myeloma according to induction therapy with thalidomide/dexamethasone (TD) with or without bortezomib (VTD)
Giralt, Sergio
Thandi, Rupi
Qazilbash, Muzaffar
Mendoza, Floralyn
Han, Eric
Hosing, Chitra
Wang, Michael
Thomas, Sheeba
Alexanian, Raymond
Champlin, Richard
Weber, Donna
[J]. BLOOD, 2007, 110 (11) : 288A - 288A
[9] Correlation of peripheral blood plasma levels of angiogenesis factors with treatment of thalidomide (T) or thalidomide-dexamethasone (TD) in prevoiusly untreated patients with multiple myeloma (MM).
Weber, D
Albitar, M
Delasalle, K
Dey, A
Rankin, K
Gavino, M
Walker, P
Alexanian, R
[J]. BLOOD, 2002, 100 (11) : 808A - 809A
[10] Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) versus Thalidomide-Dexamethasone to treat multiple myeloma (MM) patients progressing or relapsing after autologous transplantation: the MMVAR trial, a study from the myeloma subcommittee of the Chronic Leukemia Working Party of the EBMT
Garderet, L.
Iacobelli, S.
Moreau, P.
Onida, F.
Koenecke, C.
Pabst, T.
Doyen, C.
Crawley, C.
Hajek, R.
Linkesch, W.
Harousseau, J. L.
Michallet, M.
Doran, Z.
de Witte, T.
Niederwieser, D.
Gahrton, G.
Morris, C.
[J]. BONE MARROW TRANSPLANTATION, 2009, 43 : S30 - S30

← 1 2 3 4 →